ReproNovo - Model RPN-002 (Nolasiban) - Embryo Implantation Enhancer
Our second asset RPN-002 (nolasiban) is an oxytocin receptor antagonist. RPN-002 has the potential to increase pregnancy rates and live birth rates in women undergoing embryo transfer after IVF. Clinical studies have demonstrated that blocking oxytocin receptor activation can decrease uterine contractions, increase blood flow to the lining of the uterus and help it better prepare for pregnancy by enhancing its ability to support embryo implantation.
Adenomyosis
With RPN-002, we also aim to develop a treatment for the symptoms of adenomyosis. Adenomyosis is a common uterine condition where tissue from the lining of the uterus grows into the muscular area of the uterus. This condition causes a variety of painful symptoms, including severe menstrual cramps, heavy and prolonged periods, pain during intercourse and difficulties in conceiving. Increased activation of the oxytocin receptor and signaling could play a key role in the development and progression of adenomyosis. Oxytocin receptors are overexpressed in adenomyosis patients, and its levels have been shown to correlate with some of the symptoms. RPN-002 may help alleviate the signs and symptoms of adenomyosis by correcting abnormal uterine contractility, reducing local tissue inflammation, relieving menstrual pain and potentially increase fertility rates.